Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2009 3
2010 1
2011 1
2012 1
2013 1
2014 2
2015 2
2016 2
2018 1
2019 2
2020 5
2021 6
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I, Romagnoli D, Galardi F, De Luca F, Biagioni C, Curigliano G, Criscitiello C, Minisini AM, Moretti E, Risi E, Guarducci C, Nardone A, Biganzoli L, Benelli M, Malorni L. Migliaccio I, et al. Among authors: galardi f. JCO Precis Oncol. 2024 Feb;8:e2300285. doi: 10.1200/PO.23.00285. JCO Precis Oncol. 2024. PMID: 38427931 Clinical Trial.
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
Salvianti F, Gelmini S, Mancini I, Pazzagli M, Pillozzi S, Giommoni E, Brugia M, Di Costanzo F, Galardi F, De Luca F, Castiglione F, Messerini L, Pinzani P, Antonuzzo L. Salvianti F, et al. Among authors: galardi f. Br J Cancer. 2021 Jul;125(1):94-100. doi: 10.1038/s41416-021-01399-6. Epub 2021 May 5. Br J Cancer. 2021. PMID: 33953347 Free PMC article.
Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine.
Lilli C, Biggeri A, Zingaretti C, Vertogen B, Frassineti V, Vespignani R, Grossi V, Florescu C, Matteucci L, Pazzi C, Bongiovanni A, Limarzi F, Fausti V, Bertoni L, Donati C, Galardi F, Gentili N, Mazza F, Martinelli G, Nanni O. Lilli C, et al. Among authors: galardi f. Epidemiol Prev. 2021 Jan-Apr;45(1-2):28-36. doi: 10.19191/EP21.1-2.P028.036. Epidemiol Prev. 2021. PMID: 33884840 Free article. Clinical Trial. English.
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Galardi F, De Luca F, Biagioni C, Migliaccio I, Curigliano G, Minisini AM, Bonechi M, Moretti E, Risi E, McCartney A, Benelli M, Romagnoli D, Cappadona S, Gabellini S, Guarducci C, Conti V, Biganzoli L, Di Leo A, Malorni L. Galardi F, et al. Breast Cancer Res. 2021 Mar 24;23(1):38. doi: 10.1186/s13058-021-01415-w. Breast Cancer Res. 2021. PMID: 33761970 Free PMC article. Clinical Trial.
Cell-Free DNA-Methylation-Based Methods and Applications in Oncology.
Galardi F, Luca F, Romagnoli D, Biagioni C, Moretti E, Biganzoli L, Leo AD, Migliaccio I, Malorni L, Benelli M. Galardi F, et al. Biomolecules. 2020 Dec 15;10(12):1677. doi: 10.3390/biom10121677. Biomolecules. 2020. PMID: 33334040 Free PMC article. Review.
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Nanni O, Viale P, Vertogen B, Lilli C, Zingaretti C, Donati C, Masini C, Monti M, Serra P, Vespignani R, Grossi V, Biggeri A, Scarpi E, Galardi F, Bertoni L, Colamartini A, Falcini F, Altini M, Massa I, Gaggeri R, Martinelli G. Nanni O, et al. Among authors: galardi f. Trials. 2020 Jul 31;21(1):689. doi: 10.1186/s13063-020-04527-4. Trials. 2020. PMID: 32736597 Free PMC article.
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M, Gentili N, Balzi W, Musuraca G, Maltoni R, Masini C, Galardi F, Bertoni L, Massa I. Altini M, et al. Among authors: galardi f. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):503-509. doi: 10.1080/14737167.2020.1764353. Epub 2020 May 13. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32403958
28 results